Abstract:Background: Sorafenib is an effective treatment for radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC), but adverse events limit its use. We investigated the synergistic anticancer effects of silencing lncRNA-PVT1 and sorafenib in papillary thyroid carcinoma (PTC) cell lines.Methods: B-CPAP, TPC-1, IHH-4 and K1 papillary thyroid carcinoma cell lines were used. A small interfering RNA (siRNA)-PVT1 sequence was used to silence lncRNA-PVT1 expression. Cell proliferation, migration and invasion, a… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.